Irbesartan Bluepharma

Irbesartan, the active ingredient in Irbesartan Bluepharma, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure and related cardiovascular conditions in adult patients.

GNH USA supplies Irbesartan Bluepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to lower blood pressure and protect target organs.

- Hypertension: lowers systemic blood pressure by blocking angiotensin II‑mediated vasoconstriction. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: reduces cardiac workload and improves symptoms by decreasing afterload.

Irbesartan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Elevated blood potassium

Serious or Rare Side Effects: - Angioedema - Severe hyperkalemia - Acute kidney injury - Hepatic dysfunction

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure safe use.

- Monitor blood pressure: check regularly to assess therapeutic response. - Assess renal function: evaluate serum creatinine and eGFR before and during treatment. - Check serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents. - Use caution in pregnancy: drug is contraindicated in the second and third trimesters. - Avoid in severe hepatic impairment: limited data support safe use. - Store at below 25°C: keep in the original packaging, protect from moisture.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Combined therapy with ACE inhibitors or other ARBs: heightened chance of hyperkalemia and hypotension. - Use with potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - Co‑administration with NSAIDs: can reduce renal perfusion and worsen kidney function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, requiring serum monitoring. - Rifampin: induces metabolism and can lower Irbesartan plasma concentrations. - Cyclosporine: may increase serum creatinine, necessitating renal function checks.